Coronavirus: NAFDAC Approves Chloroquine for Clinical Trials

The National Agency for Food and Drug Administration and Control ( NAFDAC ) has approved the production of chloroquine for clinical trials in the search for a cure for COVID19.

This was made known by the Director-General of the agency, Mojisola Adeyeye, on Friday.

The DG said that NAFDAC is not approving Chloroquine for the treatment of COVID-19 but for clinical trials to find treatment for the virus.

“NAFDAC is not approving Chloroquine as a product that can be used for Coronavirus because there is no submission to us for registration but because it is under clinical trials, NAFDAC approves medicines meant for clinical trials.

Therefore the medicine is being approved just for the clinical trials,” Adeyeye said. She, therefore, called on experts and researchers that are interested in doing a clinical trial on Chloroquine to approach approved outlets.

“Right now, we have asked one company to make a batch of Chloroquine for the purpose of the clinical trial,” Adeyeye added.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.